基于AIE的癌症免疫治疗平台的最新进展
Ziyi Chen1, Xueping Li2, Qian Liu3
1Frontiers Science Center for New Organic Matter, State Key Laboratory of Medicinal Chemical Biology, Key Laboratory of Bioactive Materials, Ministry of Education, and College of Life Sciences, Nankai University, Tianjin 300071, China.
聚合诱导排放光原体 (AIEgens) 通过实现精确的成像和向治疗来增强癌症免疫疗法. 这些材料促进免疫反应,并与免疫检查点抑制剂协同作用,以改善癌症治疗结果.
科学领域:
- 纳米医学是一种纳米医学.
- 生物医学工程 生物医学工程
- 免疫学 免疫学 免疫学
背景情况:
- 聚合诱导排放发光剂 (AIEgens) 在聚合时表现出增强的光和光稳定性.
- AIEgens正在成为纳米医学的强大工具,用于theranostics,特别是在癌症治疗中.
研究的目的:
- 审查AIEgens在癌症免疫疗法的纳米医学中的整合.
- 突出AIEgens作为治疗平台的优势,机制和进步.
主要方法:
- 在纳米医学和癌症免疫治疗中对AIEgens的文献综述.
- 分析AIEgens在免疫反应调节和协同疗法的作用.
主要成果:
- 艾因基因促进实时图像引导治疗,诱导细胞死亡,并重新编程瘤微环境.
- 艾因基因通过调节免疫反应和强化免疫检查点抑制来增强癌症免疫疗法.
结论:
- AIEgens代表了先进癌症免疫治疗的有前途平台,在纳米医学中提供了多功能应用.
- 对AIEGEN的进一步研究将推动光热疗法和个性化癌症治疗的创新.
更多相关视频
09:56A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
11:08Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
Published on: February 14, 2025
相关概念视频
Tumor Immunotherapy
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
